Bli medlem
Bli medlem

Du är här



Press release May 20 2016

CareDx, Inc ("CareDx") announced on 8 April 2016 that the company
completes its public offer to the shareholders of Allenex AB (publ),
("Allenex"). After completion of the offer, CareDx holds
approximately 98.3 percent of the shares of Allenex and has notified
Allenex' board of directors that CareDx has resolved to initiate
compulsory acquisition proceedings regarding the remaining shares.

In light of the above, Allenex' board of directors does not consider
it motivated for Allenex to remain a listed company and has therefore
decided to apply for de-listing of the Allenex share from Nasdaq
Stockholm. The last day of trading in the Allenex share will be
announced as soon as a notification thereof has been received from
Nasdaq Stockholm.

For more information please contact:
Anders Karlsson, CEO Allenex AB, and ph.: +4670-918 00 10, e-mail:

Allenex AB discloses the information provided herein pursuant to the
Securities Markets Act and /or the Financial Instruments Trading Act.
The information was submitted for publication on May 20, 2016, at
08:00 CET. Allenex is a life science-company that develops,
manufacture, market and sell products for safer transplants of organs
and bone marrow on the global market. Allenex is listed on NASDAQ OMX
Stockholm Small Cap (ticker: ALNX). 57 persons are employed in the
Allenex group.


Författare WKR

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.